carbamates and Pulmonary Arterial Hypertension studies

carbamates and Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension: A progressive rare pulmonary disease characterized by high blood pressure in the PULMONARY ARTERY.

Research Excerpts

Excerpt	Relevance	Reference
" Dosage was then up-titrated as tolerated over the course of the 9-week dose-titration period, to a maximum total daily dose of 600 μg (300 μg twice daily)."	2.90	Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. ( Adams, J; Cabell, C; D'Souza, G; Escribano Subías, P; Farber, H; Grundy, J; Hoffmann, I; Keogh, A; Klassen, P; McLaughlin, V; Ristic, A; Rubin, L; Shanahan, W; Sood, N; Torres, F; Zhang, J, 2019)

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

0 (0.00)

29.6817

2010's

1 (100.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Torres, F	1
Farber, H	1
Ristic, A	1
McLaughlin, V	1
Adams, J	1
Zhang, J	1
Klassen, P	1
Shanahan, W	1
Grundy, J	1
Hoffmann, I	1
Cabell, C	1
Escribano Subías, P	1
Sood, N	1
Keogh, A	1
D'Souza, G	1
Rubin, L	1

Studies

Torres, F

Farber, H

Ristic, A

McLaughlin, V

Adams, J

Zhang, J

Klassen, P

Shanahan, W

Grundy, J

Hoffmann, I

Cabell, C

Escribano Subías, P

Sood, N

Keogh, A

D'Souza, G

Rubin, L

Clinical Trials (1)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of Ralinepag, an Oral IP Receptor Agonist, in Patients With Pulmonary Arterial Hypertension[NCT02279160]	Phase 2	61 participants (Actual)	Interventional	2014-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial

Phase

Enrollment

Study Type

Start Date

Status

A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of Ralinepag, an Oral IP Receptor Agonist, in Patients With Pulmonary Arterial Hypertension[NCT02279160]

Phase 2

61 participants (Actual)

Interventional

2014-12-31

Completed

[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in 6-minute Walk Distance (6MWD) in Patients With PAH

The 6MWT was conducted according to the modified guidelines issued by the American Thoracic Society prior to Day 1 of the dose titration period and at the end of the maintenance period (Week 22). (NCT02279160)
Timeframe: Baseline and 22 Weeks

Intervention	meters (Least Squares Mean)
APD811	36.2
Placebo	29.4

Intervention

meters (Least Squares Mean)

APD811

36.2

Placebo

29.4

Change From Baseline in Pulmonary Vascular Resistance (PVR)

Measurements of PVR from right heart catheterization were obtained prior to Day 1 of the dose titration period and at the end of the maintenance period (Week 22), approximately 4 hours after the last dose of study drug. (NCT02279160)
Timeframe: Baseline and 22 Weeks

Intervention	dyn*sec/cm^5 (Geometric Mean)
APD811	514.6
Placebo	512.0

Intervention

dyn*sec/cm^5 (Geometric Mean)

APD811

514.6

Placebo

512.0

Article	Year
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. The European respiratory journal, 2019, Volume: 54, Issue:4 Topics: Acetates; Adult; Aged; Carbamates; Double-Blind Method; Drug Therapy, Combination; Endothelin Recept	2019

Article

Year

Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial.

The European respiratory journal, 2019, Volume: 54, Issue:4

Topics: Acetates; Adult; Aged; Carbamates; Double-Blind Method; Drug Therapy, Combination; Endothelin Recept

2019